Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study

Cilli et al., Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 38% Improvement Relative Risk Favipiravir for COVID-19  Cilli et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 46 patients in Turkey Lower mortality with favipiravir (not stat. sig., p=0.51) c19early.org Cilli et al., Respiratory Medicine and.., Mar 2022 Favorsfavipiravir Favorscontrol 0 0.5 1 1.5 2+
Retrospective 46 idiopathic pulmonary fibrosis patients with COVID-19 in Turkey, showing lower mortality with favipiravir in unadjusted results, without statistical significance.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 37.5% lower, RR 0.62, p = 0.51, treatment 5 of 23 (21.7%), control 8 of 23 (34.8%), NNT 7.7, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cilli et al., 3 Mar 2022, retrospective, Turkey, peer-reviewed, 10 authors.
This PaperFavipiravirAll
Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
Aykut Cilli, Ismail Hanta, Fatih Uzer, Funda Coskun, Can Sevinc, Pelin Pınar Deniz, Mehmet Parlak, Ersoy Altunok, Kemal Can Tertemiz, Ahmet Ursavas
Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Background: There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) infection in patients with idiopathic pulmonary fibrosis (IPF). The objective of this study is to describe the characteristics and outcomes of IPF patients confirmed COVID-19 infection. Methods: In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with known IPF and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records. Results: Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65 § 10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was significantly associated with lower DLCO/VA, long term oxygen therapy and consolidation finding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated with hospitalization or mortality. Conclusions: IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain key to protect IPF patients.
Conflict of Interest None.
References
Aloufi, Traboulsi, Ding, Fonseca, Nair et al., Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: the forgotten cell in COVID-19, Am J Physiol Lung Cell Mol Physiol, doi:10.1152/ajplung.00455.2020
Drake, Docherty, Harrison, Quint, Adamali et al., Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study, Am J Respir Crit Care Med, doi:10.1164/rccm.202007-2794OC
Esposito, Menon, Ghosh, Putman, Fredenburgh et al., Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study, Am J Respir Crit Care Med, doi:10.1164/rccm.202006-2441LE
Gallay, Uzunhan, Borie, Lazor, Rigaud et al., Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease, Am J Respir Crit Care Med, doi:10.1164/rccm.202007-2638LE
George, Wells, Jenkins, Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy, Lancet Respirat Med, doi:10.1016/S2213-2600(20)30225-3
Huang, Zhang, Chen, Zhang, Wei et al., Clinical characteristics of COVID-19 in patients with pre-existing ILD: a retrospective study in a single center in Wuhan, China, J Med Virol, doi:10.1002/jmv.26174
Lee, Choi, Yang, Lee, Park et al., Interstitial lung disease increases susceptibility to and severity of COVID-19, Eur Respir J, doi:10.1183/13993003.04125-2020
Li, Liu, Hsu, Lin, Hsu et al., Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19, Part Fibre Toxicol, doi:10.1186/s12989-021-00404-3
Li, Wu, Wu, Guo, Chen et al., The clinical and chest CT features associated with severe and critical COVID-19 pneumonia, Invest Radiol, doi:10.1097/RLI.0000000000000672
Naqvi, Lakhani, Sohail, Maurer, Sofka et al., Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis, BMJ Open Respir Res, doi:10.1136/bmjresp-2021-000969
Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med, doi:10.1111/joim.13091
Podolanczuk, Richeldi, COVID-19 and interstitial lung disease: keep them separate, Am J Respir Crit Care Med, doi:10.1164/rccm.202010-3918ED
Raghu, Collard, Egan, Martinez, Behr et al., An Official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, doi:10.1164/rccm.2009-040GL
Rajasurya, Gunasekaran, Damarla, Kolluru, A Fatal case of coronavirus disease 2019 (COVID-19) in a patient with idiopathic pulmonary fibrosis, Cureus n, doi:10.7759/cureus.8432
Tuite, Fisman, Odutayo, Bobos, Allen et al., COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern, Ontario COVID-19 Science Advisory Table, doi:10.47326/ocsat.2021.02.18.1.0
Wong, Fidler, Marcoux, Johannson, Assayag et al., Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic, Chest, doi:10.1016/j.chest.2020.04.019
Ye, Zhang, Wang, Huang, Song, Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review, Eur Radiol, doi:10.1007/s00330-020-06801-0
Yuan, Yin, Tao, Tan, Hu, Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China, PLoS ONE, doi:10.1371/journal.pone.0230548
{ 'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T15:18:05Z', 'timestamp': 1648912685541}, 'reference-count': 19, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T00:00:00Z', 'timestamp': 1651363200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Respiratory Medicine and Research'], 'published-print': {'date-parts': [[2022, 5]]}, 'DOI': '10.1016/j.resmer.2022.100900', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 3]], 'date-time': '2022-03-03T01:30:28Z', 'timestamp': 1646271028000}, 'page': '100900', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study'], 'prefix': '10.1016', 'volume': '81', 'author': [ {'given': 'Aykut', 'family': 'Cilli', 'sequence': 'first', 'affiliation': []}, {'given': 'Ismail', 'family': 'Hanta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fatih', 'family': 'Uzer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Funda', 'family': 'Coskun', 'sequence': 'additional', 'affiliation': []}, {'given': 'Can', 'family': 'Sevinc', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pelin Pınar', 'family': 'Deniz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehmet', 'family': 'Parlak', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ersoy', 'family': 'Altunok', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kemal Can', 'family': 'Tertemiz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmet', 'family': 'Ursavas', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.resmer.2022.100900_bib0001', 'unstructured': 'WHO Coronavirus (COVID-19) Dashboard n.d. https://covid19.who.int ' '(accessed October 27, 2021).'}, { 'key': '10.1016/j.resmer.2022.100900_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '1069', 'DOI': '10.1016/j.chest.2020.04.019', 'article-title': 'Practical considerations for the diagnosis and treatment of fibrotic ' 'interstitial lung disease during the coronavirus disease 2019 pandemic', 'volume': '158', 'author': 'Wong', 'year': '2020', 'journal-title': 'Chest'}, { 'key': '10.1016/j.resmer.2022.100900_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '807', 'DOI': '10.1016/S2213-2600(20)30225-3', 'article-title': 'Pulmonary fibrosis and COVID-19: the potential role for antifibrotic ' 'therapy', 'volume': '8', 'author': 'George', 'year': '2020', 'journal-title': 'Lancet Respirat Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '1656', 'DOI': '10.1164/rccm.202007-2794OC', 'article-title': 'Outcome of hospitalization for COVID-19 in patients with interstitial ' 'lung disease. An international multicenter study', 'volume': '202', 'author': 'Drake', 'year': '2020', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '1710', 'DOI': '10.1164/rccm.202006-2441LE', 'article-title': 'Increased odds of death for patients with interstitial lung disease and ' 'COVID-19: a case-control study', 'volume': '202', 'author': 'Esposito', 'year': '2020', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0006', 'doi-asserted-by': 'crossref', 'article-title': 'Interstitial lung disease increases susceptibility to and severity of ' 'COVID-19', 'author': 'Lee', 'year': '2021', 'journal-title': 'Eur Respir J', 'DOI': '10.1183/13993003.04125-2020'}, { 'key': '10.1016/j.resmer.2022.100900_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '245', 'DOI': '10.1164/rccm.202007-2638LE', 'article-title': 'Risk factors for mortality after COVID-19 in patients with preexisting ' 'interstitial lung disease', 'volume': '203', 'author': 'Gallay', 'year': '2021', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '788', 'DOI': '10.1164/rccm.2009-040GL', 'article-title': 'An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: ' 'evidence-based guidelines for diagnosis and management', 'volume': '183', 'author': 'Raghu', 'year': '2011', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0009', 'series-title': 'Ontario COVID-19 Science Advisory Table', 'article-title': 'COVID-19 hospitalizations, ICU admissions and deaths associated with ' 'the new variants of concern', 'author': 'Tuite', 'year': '2021'}, { 'key': '10.1016/j.resmer.2022.100900_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '192', 'DOI': '10.1111/joim.13091', 'article-title': 'COVID-19 diagnosis and management: a comprehensive review', 'volume': '288', 'author': 'Pascarella', 'year': '2020', 'journal-title': 'J Intern Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0011', 'doi-asserted-by': 'crossref', 'article-title': 'Clinical characteristics of COVID-19 in patients with pre-existing ILD: ' 'a retrospective study in a single center in Wuhan, China', 'author': 'Huang', 'year': '2020', 'journal-title': 'J Med Virol', 'DOI': '10.1002/jmv.26174'}, { 'key': '10.1016/j.resmer.2022.100900_bib0012', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/bmjresp-2021-000969', 'article-title': 'Patients with idiopathic pulmonary fibrosis have poor clinical outcomes ' 'with COVID-19 disease: a propensity matched multicentre research ' 'network analysis', 'volume': '8', 'author': 'Naqvi', 'year': '2021', 'journal-title': 'BMJ Open Respir Res'}, { 'key': '10.1016/j.resmer.2022.100900_bib0013', 'doi-asserted-by': 'crossref', 'unstructured': 'Rajasurya V., Gunasekaran K., Damarla V., Kolluru A. A Fatal case of ' 'coronavirus disease 2019 (COVID-19) in a patient with idiopathic ' 'pulmonary fibrosis. Cureus n.d. ;12:e8432. ' 'https://doi.org/10.7759/cureus.8432.', 'DOI': '10.7759/cureus.8432'}, { 'key': '10.1016/j.resmer.2022.100900_bib0014', 'doi-asserted-by': 'crossref', 'first-page': '11', 'DOI': '10.1186/s12989-021-00404-3', 'article-title': 'Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic ' 'pulmonary fibrosis: a potential role in severe COVID-19', 'volume': '18', 'author': 'Li', 'year': '2021', 'journal-title': 'Part Fibre Toxicol'}, { 'key': '10.1016/j.resmer.2022.100900_bib0015', 'doi-asserted-by': 'crossref', 'first-page': 'L152', 'DOI': '10.1152/ajplung.00455.2020', 'article-title': 'Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: ' 'the forgotten cell in COVID-19', 'volume': '320', 'author': 'Aloufi', 'year': '2021', 'journal-title': 'Am J Physiol Lung Cell Mol Physiol'}, { 'key': '10.1016/j.resmer.2022.100900_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '1614', 'DOI': '10.1164/rccm.202010-3918ED', 'article-title': 'COVID-19 and interstitial lung disease: keep them separate', 'volume': '202', 'author': 'Podolanczuk', 'year': '2020', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '10.1016/j.resmer.2022.100900_bib0017', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0230548', 'article-title': 'Association of radiologic findings with mortality of patients infected ' 'with 2019 novel coronavirus in Wuhan, China', 'volume': '15', 'author': 'Yuan', 'year': '2020', 'journal-title': 'PLoS ONE'}, { 'key': '10.1016/j.resmer.2022.100900_bib0018', 'doi-asserted-by': 'crossref', 'first-page': '327', 'DOI': '10.1097/RLI.0000000000000672', 'article-title': 'The clinical and chest CT features associated with severe and critical ' 'COVID-19 pneumonia', 'volume': '55', 'author': 'Li', 'year': '2020', 'journal-title': 'Invest Radiol'}, { 'key': '10.1016/j.resmer.2022.100900_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '4381', 'DOI': '10.1007/s00330-020-06801-0', 'article-title': 'Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a ' 'pictorial review', 'volume': '30', 'author': 'Ye', 'year': '2020', 'journal-title': 'Eur Radiol'}], 'container-title': ['Respiratory Medicine and Research'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2590041222000174?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2590041222000174?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 3, 23]], 'date-time': '2022-03-23T17:37:46Z', 'timestamp': 1648057066000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2590041222000174'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 5]]}, 'references-count': 19, 'alternative-id': ['S2590041222000174'], 'URL': 'http://dx.doi.org/10.1016/j.resmer.2022.100900', 'relation': {}, 'ISSN': ['2590-0412'], 'issn-type': [{'value': '2590-0412', 'type': 'print'}], 'subject': ['Pulmonary and Respiratory Medicine'], 'published': {'date-parts': [[2022, 5]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Characteristics and outcomes of COVID-19 patients with IPF: A multi-center ' 'retrospective study', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Respiratory Medicine and Research', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.resmer.2022.100900', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 SPLF and Elsevier Masson SAS. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '100900'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit